Navigation Links
Amicus Therapeutics Announces First Quarter 2008 Financial Results
Date:5/13/2008

Strong financial position supports clinical focus on advancing drug

candidates for treatment of lysosomal storage disorders

CRANBURY, N.J., May 13 /PRNewswire-FirstCall/ -- Amicus Therapeutics (Nasdaq: FOLD), a biopharmaceutical company developing small molecule, orally-administered pharmacological chaperones for the treatment of human genetic diseases, today announced financial results for the first quarter of 2008. On a reported basis calculated in accordance with U.S. Generally Accepted Accounting Principles (GAAP), Amicus announced a net loss attributable to common stockholders of $0.34 per share ($0.28 per share on a non-GAAP basis) for the three months ended March 31, 2008. As of March 31, 2008, cash, cash equivalents, and marketable securities totaled $154.6 million.

"In the first quarter of 2008, we continued to advance our three lead clinical development programs. We also reported data from multiple clinical trials that add to the growing body of evidence demonstrating that treatment with our oral pharmacological chaperone drug candidates has the potential to benefit patients with Fabry, Gaucher and Pompe disease," said John F. Crowley, President and CEO of Amicus Therapeutics. "In the months ahead in 2008, we will be focused on advancing the global regulatory plan for Amigal Phase 3 development, evaluating opportunities for additional clinical studies in Gaucher and Pompe disease, as well as on identifying new therapeutic areas for applying our pharmacological chaperone technology platform."

Program Advancements

Fabry Disease:

Amigal(TM) (migalastat hydrochloride) is an investigational, oral therapeutic being developed for the treatment of Fabry disease. In March, clinical investiga
'/>"/>

SOURCE Amicus Therapeutics
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12

Related biology technology :

1. Amicus Therapeutics to Present at the Merrill Lynch Global Pharmaceutical, Biotech & Medtech 2007 Conference
2. Amicus Therapeutics Announces Third Quarter 2007 Financial Results
3. Meredith Martin Addy Named Chair of AIPLAs Amicus Committee
4. Amicus Therapeutics to Present at the Lazard Capital Markets Fourth Annual Healthcare Conference
5. Amicus Therapeutics to Host R&D Day
6. Amicus Therapeutics Announces Positive Results From Phase 2 Clinical Trials of Amigal(TM) for Fabry Disease
7. Amicus Therapeutics Announces Fourth Quarter and Full Year 2007 Financial Results & Program Advancements
8. Amicus Therapeutics to Present at the Merrill Lynch Global Pharmaceutical, Biotechnology & Medical Device Conference
9. Amicus Therapeutics to Present at the BIO CEO & Investor Conference 2008
10. Amicus Therapeutics Presents Positive Data from Phase 2 Clinical Trial of Plicera(TM) for Gaucher Disease
11. Amicus Therapeutics to Present at the Morgan Stanley Global Healthcare Unplugged Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... laureate Herbert Kroemer famously observed, referring to the ... where layers of different materials meet. In today,s ... of metal oxides are becoming increasingly prominent, with ... superconductors, ferroelectrics and multiferroics. Realizing the vast potential ...
(Date:1/15/2014)... Cynvenio, a cancer diagnostics company focused ... analysis of tumor cells in the bloodstream, today announced ... decision support application powered by CollabRx, Inc. , ... test, Therapy Finder will provide breast cancer patients and ...
(Date:1/15/2014)... More than 5 million Americans are ... 3 seniors will die with Alzheimer’s or another dementia, ... have shocked many Americans into looking for ways to ... tragic age-related cognitive disorders. Jonathan Weisman, president of Biohack ...
(Date:1/15/2014)... (PRWEB) January 15, 2014 Freeslate, ... solutions, today announced that Lupin Limited, one of India’s ... CM Protégé PharmD System for high throughput ... India, is focused on a wide range of quality, ...
Breaking Biology Technology:A deeper look at interfaces 2Cynvenio Offers New Breast Cancer Therapy Finder Application for its ClearID Breast Cancer Genomic Test 2Cynvenio Offers New Breast Cancer Therapy Finder Application for its ClearID Breast Cancer Genomic Test 3Biohack Pure Offers 5 Tips for Increasing Memory in 2014 2Lupin Selects Freeslate’s CM Protégé PharmD System to Accelerate Polymorph Screening for Drug Development 2Lupin Selects Freeslate’s CM Protégé PharmD System to Accelerate Polymorph Screening for Drug Development 3
... Acquisition Extends Elsevier,s Ability to Gather Global Healthcare News and, ... Increase ... Business Value for Customers, PHILADELPHIA, March 10 ... information, announced,today that it has acquired Windhover Information Inc., a ...
... March 10 Caliper Life,Sciences, Inc. (Nasdaq: ... the,Cowen and Company 28th Annual Health Care Conference ... at 2:30 p.m. EDT. Kevin Hrusovsky, President,and CEO ... the company,s business.,The live webcast can be accessed ...
... used by Avexa to select patients and optimize ... background therapy in phase III program, SOUTH SAN FRANCISCO, ... today that the Company,has signed an agreement with AVEXA Limited (ASX: ... technology in support of,Avexa,s drug discovery and development programs., Avexa ...
Cached Biology Technology:Elsevier Acquires Windhover Information Inc., a Healthcare Business Intelligence Company 2Elsevier Acquires Windhover Information Inc., a Healthcare Business Intelligence Company 3Monogram Biosciences and Avexa Announce Exclusive Collaboration to Support New HIV Drug Discovery and Development Efforts 2Monogram Biosciences and Avexa Announce Exclusive Collaboration to Support New HIV Drug Discovery and Development Efforts 3Monogram Biosciences and Avexa Announce Exclusive Collaboration to Support New HIV Drug Discovery and Development Efforts 4Monogram Biosciences and Avexa Announce Exclusive Collaboration to Support New HIV Drug Discovery and Development Efforts 5
(Date:4/17/2014)... our ideas about domestication derive from Charles Darwin, ... British animal-breeding practices during the 19th century, a ... , It is from Darwin that we ... captive animals from wild species and total human ... animal management in this industrial setting has been ...
(Date:4/16/2014)... Lying forgotten in museum collections two new species of yellow-shouldered bats ... York and The Field Museum of Natural History and described in ... new additions to the genus Sturnira are part of ... the world, the third one still waiting to be officially announced. ...
(Date:4/16/2014)... far away, the top of a leaf looks like ... is actually made up of a patchwork of cells ... how these cells individually take on their own unique ... and colleagues sought to pinpoint the shape-controlling factors in ...
Breaking Biology News(10 mins):The story of animal domestication retold 2The story of animal domestication retold 3The story of animal domestication retold 4Two new species of yellow-shouldered bats endemic to the Neotropics 2For cells, internal stress leads to unique shapes 2
... tend to think in terms of tit-for-tat, an assumption ... is often viewed as a cognitive feat requiring memory, ... simpler, not only in other animals but in humans ... Primate Research Center, Emory University, have determined monkeys may ...
... juvenile coral reef fishes use coastal seagrass and mangrove ... reefs. But the fishes, movements, and the connections between ... realized, according to a study published September 3 in ... The findings have important implications for management and protection ...
... Institutes of Health have restored the ability to smell ... that causes congenital anosmiathe inability to smell from birth. ... structures that are essential for olfactory function. ,The ... National Institute on Deafness and Other Communications Disorders (NIDCD), ...
Cached Biology News:Reciprocity an important component of prosocial behavior 2Reciprocity an important component of prosocial behavior 3Tracking fish through a coral reef seascape 2Tracking fish through a coral reef seascape 3Tracking fish through a coral reef seascape 4NIH-funded researchers restore sense of smell in mice using genetic technique 2NIH-funded researchers restore sense of smell in mice using genetic technique 3
... Exonuclease III digests duplex DNA in ... end, 5'-overhang or nick, producing stretches of ... degradation by Exonuclease III proceeds at a ... Because the rate of exonucleolytic excision of ...
... Klenow fragment is a proteolytic ... DNA Polymerase I which ... 5 exonuclease activity, but has ... Klenow retains the polymerization fidelity ...
... RNase H degrades, as an endoribonuclease, ... DNA hybrids of natural origin, e.g. ... synthetic complexes, e.g. poly(A) x poly(dT). ... and 3-OH termini. Nearly no activity ...
... Source: E. coli strain containing an overproducing ... Ligase catalyzes the formation of a phosphodiester bond ... in duplex DNA or RNA. It repairs single-stranded ... and will join both blunt-end and cohesive-end fragments ...
Biology Products: